VolitionRx Limited (NYSE American: VNRX) announced the submission for peer review of a clinical manuscript demonstrating the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats. The study achieved 97% specificity and identified 86% of cases, marking a significant step in the development of a blood-based liquid biopsy test for feline cancer.
The technology addresses a substantial unmet need in veterinary medicine, where early detection of cancer in companion animals remains challenging. According to the company, the assay represents a commercial opportunity, with potential milestone payments and future revenue generation as it works toward product commercialization and expands its presence in the growing companion animal oncology market.
The publication of this study in a peer-reviewed journal is expected to unlock a $5 million contractual milestone payment, underscoring the financial significance of the research. VolitionRx is a multinational company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.
The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information, visit the company’s website at www.Volition.com.
The full press release is available at https://ibn.fm/ARsEY.
This development is important for the veterinary oncology field, as it offers a non-invasive diagnostic option that could significantly improve early detection rates for feline lymphoma. The high specificity and sensitivity demonstrated in the study suggest that the Nu.Q Vet assay could become a valuable tool for veterinarians, potentially leading to better treatment outcomes and quality of life for cats. For the industry, successful commercialization could open new revenue streams for VolitionRx and set a precedent for blood-based cancer testing in companion animals.
